Company profile
Schrodinger, Inc.
NASDAQ:SDGRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SGR-1505 | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05544019 | phase1 | recruiting | 2023-04-10 | 2027-11-01 | Schrödinger, Inc. | Study of SGR-1505 in Mature B-Cell Neoplasms |
| NCT05961839 | phase1 | terminated | 2023-09-27 | 2025-08-14 | Schrödinger, Inc. | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome |
| NCT06463340 | phase1 | recruiting | 2024-06-18 | 2026-10-31 | Schrödinger, Inc. | Study of SGR-3515 In Participants With Advanced Solid Tumors. |
FDA applications (0)
No records yet.